One of UK's most prescribed drugs could reduce death rate of common blood cancer
One of the most prescribed drugs in the UK could reduce the risk of dying from blood cancer by more than 60 per cent, a study has revealed.
Statins, a cholesterol-lowering medication taken by more than 7million people in the UK, lowers the risk of heart disease, which can lead to heart attacks or strokes.
But it's also been suggested to reduce the death rates of several cancers, including Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), according to a study published today in the journal Blood Advances.
These are both types of slow-growing cancers. CLL starts in the blood-forming cells of the bone marrow and is a common form of leukaemia. SLL affects the same type of cells but starts in lymphoid tissues such as the spleen instead of in the blood-forming cells.
Researchers analysed data from 1,467 patents with CLL or SLL who participated in four international trials conducted between 2012 and 2019.
Each patient was either newly diagnosed, their blood cancer had come back or had not responded to prior treatment.
These trials saw patients randomly assigned ibrutinib, a targeted cancer drug, either alone or in combination with other anti-cancer drugs, or to a drug regimen that did not include ibrutinib.
A total of 424 patients (29 per cent) were taking a statin at the time they started treatment across the four clinical trials which looked at how long patients lived after starting treatment. They were followed up after five years for overall survival and 22 months for progression-free survival.
Researchers discovered that patients who took a statin had a 61 per cent reduced risk of dying from their cancer, a 38 per cent reduction in death of any cause and a 26 per cent reduced risk of disease progression.
Researchers adjusted their analysis for variables including each patient's diagnosis, age, sex, weight, disease severity, length of time since their diagnosis, number of co-existing illnesses, use of other medications for heart conditions or high blood pressure, and the specific anti-cancer treatment regimen received.
'Our results highlight a strong link between statin use and improved survival in this patient population,' said the study's principal investigator, Ahmad Abuhelwa, PhD, an assistant professor of pharmacy practice and pharmacotherapeutics at the University of Sharjah in the United Arab Emirates.
He added: 'These findings don't allow us to say for certain that statins directly improve cancer outcomes.
'However, the fact that this association remained strong even after accounting for multiple factors makes it an important area for future research.'
As next steps, he recommended conducting laboratory studies to better understand how statins may influence cancer biology, as well as prospective clinical trials in which patients with CLL or SLL are randomly assigned to take a statin or not.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 days ago
- Daily Mail
Statins almost halve the risk of death in patients critically ill with sepsis
Taking statins can improve the chances of surviving sepsis by 40 per cent, a trial has found. Sepsis can occur when the body's immune system overreacts to an infection and attacks its own organs. It is notoriously difficult to spot because the telltale symptoms, such as a fever and muscle pain, can be easily mistaken for signs of a common cold or other infection. Statins lower cholesterol to prevent heart attacks and strokes and are taken by around 5 million adults in the UK. But experts say they have other benefits, including reducing inflammation and fighting bacteria that can ultimately lead to sepsis. The study compared survival rates of sepsis patients given statins and those who were not during a hospital stay. It found the pills reduced the risk of death for those critically ill with the condition by 39 per cent. The study compared survival rates of sepsis patients given statins and those who were not during a hospital stay. It found the pills reduced the risk of death for those critically ill with the condition by 39 per cent (file image) In intensive care, 14.3 per cent of 6,000 sepsis patients given statins died within 28 days, compared with 23.4 per cent of 6,000 patients who were not. For those no longer in a critical condition, 11 per cent given statins died compared to 19 per cent who were not. Dr Caifeng Li, of Tianjin Medical University General Hospital in China and the study's author said: 'These results suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Researchers believe the drugs may help with sepsis by helping to combat bacteria directly, reducing the toll infection takes on the body. Earlier this year another study found the pills could also slash dementia risk – even in patients who don't have high cholesterol. The sepsis study, published in the journal Frontiers in Immunology, was based on data from thousands of patients at an Israeli hospital over a decade. Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'This study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.' Sepsis is known as the 'silent killer'. For every hour of delay in treatment, a patient's chance of dying increases 8 per cent. If caught early, it can be treated with antibiotics and fluids. Symptoms include slurred speech or confusion, shivering or muscle pain, passing no urine in a day, severe breathlessness and mottled or discoloured skin. Blood test to spot Alzheimer's early A Blood test for Alzheimer's can accurately detect the disease early, a study suggests. The test was 95 per cent accurate in identifying people with memory problems. It also scored 82 per cent for specificity, which means it was highly accurate in ruling out people without dementia. The study, published in the journal Alzheimer's and Dementia, found proteins amyloid beta 42/40 and p-tau217 in blood plasma can be examined to diagnose the condition. The study was carried out on more than 500 people in an outpatient memory clinic. The blood test has already been approved by the Food and Drug Administration regulator in the US.
The Independent
3 days ago
- The Independent
Critically ill patients with sepsis more likely to survive when given statins
Research indicates that critically ill sepsis patients who receive statins may have a higher chance of survival. A study of 6,000 sepsis patients given statins showed 14.3 per cent died within 28 days, compared to 23.4 per cent of 6,000 patients who did not receive statins, equating to a 39% reduced risk of death. The study, conducted using data from a hospital in Israel between 2008 and 2019, also found lower mortality rates in intensive care and overall hospital stays for statin users. Dr. Caifeng Li, the study's corresponding author, suggested that statins may offer a protective effect and improve outcomes for sepsis patients. Dr. Ron Daniels, founder and chief executive of the UK Sepsis Trust, supports calls for larger trials to confirm the findings, noting the potential survival benefit from the anti-inflammatory properties of statins.
The Independent
3 days ago
- The Independent
This common prescription drug could reduce deaths by sepsis, study finds
Critically ill patients with sepsis who are given statins may be more likely to survive, new research suggests. Researchers set out to explore whether the cholesterol-busting drugs may bring additional benefits for patients. The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39 per cent reduced risk of death within a month. The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins. And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In the UK, 245,000 people are affected by sepsis every year. UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
